Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501171 · ClinicalTrials.gov registry record · NA
Psychological Mobile App for Patients With AML
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT05501171: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT05501171 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501171, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study is evaluating whether a psychological mobile application (app), is efficacious in reducing anxiety and depression symptoms and improving quality of life for patients diagnosed with acute myeloid leukemia (AML) compared to a physical health promotion app.
Interventions
- BEHAVIORAL DREAMLAND
- BEHAVIORAL CERENA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2023-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05501171
The ClinicalTrials.gov registry entry for NCT05501171 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DREAMLAND is the first listed.
NCT05501171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05501171 about?
NCT05501171 is a clinical study titled "Psychological Mobile App for Patients With AML". This research study is evaluating whether a psychological mobile application (app), is efficacious in reducing anxiety and depression symptoms and improving quality of life for patients diagnosed with acute myeloid leukemia (AML) compared to a physical health promotion app.
What is the current status of trial NCT05501171?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2022-10-15. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT05501171?
The interventions under investigation include: DREAMLAND (BEHAVIORAL), CERENA (BEHAVIORAL).
Who is sponsoring clinical trial NCT05501171?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.